-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, KHBJyHX49cG+8Po98dEsdyQHFjxhIjgIkiT2nuHgr3yAItAaPUDpc7hdk97IG18A MX8uBxZujimYYaxeh5D98A== 0001045969-02-001010.txt : 20020524 0001045969-02-001010.hdr.sgml : 20020524 20020524095554 ACCESSION NUMBER: 0001045969-02-001010 CONFORMED SUBMISSION TYPE: SC 13D/A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20020524 GROUP MEMBERS: DR. JACQUES GONELLA SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: ANTARES PHARMA INC CENTRAL INDEX KEY: 0001016169 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 411350192 STATE OF INCORPORATION: MN FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13D/A SEC ACT: 1934 Act SEC FILE NUMBER: 005-47575 FILM NUMBER: 02661617 BUSINESS ADDRESS: STREET 1: 707 EAGLEVIEW BOULEVARD STREET 2: SUITE 414 CITY: EXTON STATE: PA ZIP: 19341 BUSINESS PHONE: 610-458-6200 MAIL ADDRESS: STREET 1: 707 EAGLEVIEW BOULEVARD STREET 2: SUITE 414 CITY: EXTON STATE: PA ZIP: 19341 FORMER COMPANY: FORMER CONFORMED NAME: MEDI JECT CORP /MN/ DATE OF NAME CHANGE: 19960605 FORMER COMPANY: FORMER CONFORMED NAME: ANTARES PHARMA INC /MN/ DATE OF NAME CHANGE: 20010604 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: PERMATEC HOLDING AG CENTRAL INDEX KEY: 0001135279 IRS NUMBER: 00000000 STATE OF INCORPORATION: V8 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13D/A BUSINESS ADDRESS: STREET 1: GEWERBESTRASSE 18 STREET 2: CH-4123 ALLSCHWIL CITY: SWITZERLAND STATE: V8 ZIP: 00000 BUSINESS PHONE: 41614864155 MAIL ADDRESS: STREET 1: GEWERBESTRASSE 18 STREET 2: CH-4123 ALLSCHWIL CITY: SWITZERLAND STATE: V8 ZIP: 00000 SC 13D/A 1 dsc13da.txt AMENDMENT NO. 1 TO SCHEDULE 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D AMENDMENT NO. 1 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (AMENDMENT NO. 1)* ANTARES PHARMA, INC. - ------------------------------------------------------------------------------- (Name of Issuer) Common Stock, $.01 par value per share - ------------------------------------------------------------------------------- (Title of Class of Securities) 036642106 - ------------------------------------------------------------------------------- (CUSIP Number) Lawrence M. Christian Antares Pharma, Inc. 707 Eagleview Boulevard Suite 414 Exton, PA 19341 (610) 458-6200 - ------------------------------------------------------------------------------- Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) April 23, 2002 - ------------------------------------------------------------------------------- (Date of Event which Requires Filing of this Statement) If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(b) (3) or (4), check the following box [ ]. 1 NOTE: Six copies of this statement, including all exhibits, should be filed with the Commission. See Rule 13d-1(a) for other parties to whom copies are to be sent. *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). 2 SCHEDULE 13D - --------------------- CUSIP NO. 036642106 - --------------------- - ------------------------------------------------------------------------------- 1 NAME OF REPORTING PERSON S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON Permatec Holding AG - ------------------------------------------------------------------------------- 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) [ ] (b) [X] - ------------------------------------------------------------------------------- 3 SEC USE ONLY - ------------------------------------------------------------------------------- 4 SOURCE OF FUNDS* 00 - ------------------------------------------------------------------------------- 5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITMES 2(d) or 2 (e) [ ] - ------------------------------------------------------------------------------- 6 CITIZENSHIP OR PLACE OF ORGANIZATION Switzerland - ------------------------------------------------------------------------------- 7 SOLE VOTING POWER 2,900,000 shares NUMBER OF ---------------------------------- SHARES 8 SHARED VOTING POWER BENEFICIALLY OWNED BY 0 shares EACH ---------------------------------- REPORTING 9 SOLE DISPOSITIVE POWER PERSON WITH 2,900,000 shares ---------------------------------- 10 SHARED DISPOSITIVE POWER 0 shares - ------------------------------------------------------------------------------- 3 11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 2,900,000 shares - ------------------------------------------------------------------------------- 12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES* [ ] - ------------------------------------------------------------------------------- 13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 31.5% - ------------------------------------------------------------------------------- 14 TYPE OF REPORTING* CO - ------------------------------------------------------------------------------- *SEE INSTRUCTIONS BEFORE FILLING OUT! INCLUDE BOTH SIDES OF THE COVER PAGE, RESPONSES TO ITEMS 1-7 (INCLUDING EXHIBITS) OF THE SCHEDULE, AND THE SIGNATURE ATTESTATION 4 SCHEDULE 13D - --------------------- CUSIP NO. 036642106 - --------------------- - ------------------------------------------------------------------------------- 1 NAME OF REPORTING PERSON S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON Dr. Jacques Gonella - ------------------------------------------------------------------------------- 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) [ ] (b) [X] - ------------------------------------------------------------------------------- 3 SEC USE ONLY - ------------------------------------------------------------------------------- 4 SOURCE OF FUNDS* 00 - ------------------------------------------------------------------------------- 5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITMES 2(d) or 2(e) [ ] - ------------------------------------------------------------------------------- 6 CITIZENSHIP OR PLACE OF ORGANIZATION Switzerland - ------------------------------------------------------------------------------- 7 SOLE VOTING POWER 2,750,000 shares NUMBER OF ---------------------------------- SHARES 8 SHARED VOTING POWER BENEFICIALLY OWNED BY 2,900,000 shares EACH ---------------------------------- REPORTING 9 SOLE DISPOSITIVE POWER PERSON WITH 2,750,000 shares ---------------------------------- 10 SHARED DISPOSITIVE POWER 2,900,000 shares - ------------------------------------------------------------------------------- 5 11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 5,650,000 shares - ------------------------------------------------------------------------------- 12 CHECK BOX IF THE AGGREGTE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES* [ ] - ------------------------------------------------------------------------------- 13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11) 61.4% - ------------------------------------------------------------------------------- 14 TYPE OF REPORTING* IN - ------------------------------------------------------------------------------- *SEE INSTRUCTIONS BEFORE FILLING OUT! INCLUDE BOTH SIDES OF THE COVER PAGE, RESPONSES TO ITEMS 1-7 (INCLUDING EXHIBITS) OF THE SCHEDULE, AND THE SIGNATURE ATTESTATION 6 ITEM 1. SECURITY AND ISSUER The class of security to which this statement relates is the Common Stock, par value $.01 per share, of Antares Pharma, Inc. (formerly known as Medi-Ject Corporation). The name and address of the principle executive offices of the issuer of such securities are Antares Pharma, Inc., 707 Eagleview Boulevard, Suite 414, Exton, Pennsylvania 19341. ITEM 2. IDENTITY AND BACKGROUND a) and b) The names and business addresses of the persons filing this statement are as follows: Permatec Holding AG c/o JG Consulting AG Hauptstrasse 16 4132 Muttenz, Switzerland Dr. Jacques Gonella c/o JG Consulting AG Hauptstrasse 16 4132 Muttenz, Switzerland c) Permatec Holding AG is a corporation organized under the laws of Switzerland. Dr. Jacques Gonella is Chairman of Permatec Holding AG. d) The response to this item is negative for all persons listed above. e) The response to this item is negative for all persons listed above. f) Permatec Holding AG is a Swiss corporation. Dr. Jacques Gonella is a citizen of Switzerland. ITEM 3. SOURCE AND AMOUNT OF FUNDS OR OTHER CONSIDERATION Permatec acquired its 2,900,000 shares pursuant to a stock Purchase Agreement dated as of July 14, 2000 (the "Purchase Agreement") by and among Antares Pharma, Inc. ("Antares"), Permatec Holding AG ("Permatec"), Permatec Pharma AG, Permatec Technologie AG, and Permatec NV. Pursuant to the Purchase Agreement, on January 31, 2001 (the "Closing Date") Permatec Holding AG acquired 2,900,000 shares of Antares $.01 par value common stock in exchange for all of the issued and outstanding shares of three wholly-owned subsidiaries of Permatec Holding AG: Permatec Pharma AG, Permatec Technologie AG and Permatec NV. The 2,750,000 shares held by Dr. Jacques Gonella were acquired above pursuant to the conversion by Permatec of 27,500 shares of Series C Convertible Preferred Stock, $.01 par value per share of Antares. This Series C Stock was acquired by Permatec in exchange for outstanding promissory notes of Antares held by Permatec in the aggregate amount of $ 5,500,000. Permatec held the converted shares in its name as nominee for Dr. Gonella. On April 23, 2002, the shares were transferred to the name of Dr. Gonella. ITEM 4. PURPOSE OF TRANSACTION Please see explanation set forth above with respect to Item 3 for purposes of the acquisition of securities of the issuer. The answers to Item 4 are as follows: a) Inapplicable b) Inapplicable c) Inapplicable d) Inapplicable e) Inapplicable f) Inapplicable g) Inapplicable h) Inapplicable i) Inapplicable j) Inapplicable 7 ITEM 5. INTEREST IN SECURITIES OF THE ISSUER a) Permatec Holding AG is the beneficial owner of 2,900,000* shares of $.01 par value common stock of the issuer. Dr. Jacques Gonella is the beneficial owner of 5,650,000 shares of $.01 par value common stock of the issuer. b) Permatec Holding AG has the sole power to vote and the sole dispositive power over 2,900,000 shares of $.01 par value common stock of the issuer. Dr. Jacques Gonella has the sole power to vote and the sole dispositive power over 2,750,000,shares of $.01 par value common stock of the issuer. Dr. Gonella is the Chairman of Permatec Holding AG, and owns 96.9% of its issued and outstanding stock. Thus, Dr. Gonella has shared power to vote and shared dispositive power over the 2,900,000 shares of $.01 par value common stock of the issuer held by Permatec. c) The only transaction in the common stock of the issuer that were effected by any of the reporting persons during the past sixty days are the transactions described in Item 3 above. d) No other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the subject securities. e) Not applicable ITEM 6. CONTRACTS, ARRANGEMENTS, UNDERSTANDINGS OR RELATIONSHIPS WITH RESPECT TO SECURITIES OF THE ISSUER Not Applicable ITEM 7. MATERIAL TO BE FILED AS EXHIBITS Filed as Exhibits A to this Form 13D is an agreement by the persons filing this Form 13D to make joint filing. * This number excludes any shares of the issuer held by Dr. Gonella. 8 SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. PERMATEC HOLDING AG By /s/ Dr. Jacques Gonella ------------------------------ Dr. Jacques Gonella Chairman /s/ Dr. Jacques Gonella ------------------------------ Dr. Jacques Gonella 9 EXHIBIT A AGREEMENT AS TO JOINT FILING Pursuant to Regulation Section 240.13d-1(f)(1)(iii), the undersigned acknowledge and agree that the attached Schedule 13D Amendment relating to Antares Pharma, Inc. is being filed on behalf of each of the undersigned. PERMATEC HOLDING AG By /s/ Dr. Jacques Gonella ------------------------------ Dr. Jacques Gonella Chairman By /s/ Dr. Jacques Gonella ------------------------------ Dr. Jacques Gonella 10 -----END PRIVACY-ENHANCED MESSAGE-----